The FDA has granted Sarepta Therapeutics a platform technology designation to streamline regulatory review for its gene therapy candidates, especially those targeting rare diseases. This status is part of an FDA initiative to expedite innovative treatments employing platform technologies for precision medicine. Sarepta's recognition reflects a regulatory shift aimed at fostering faster approval timelines and facilitating successive therapy development based on foundational RNA editing and gene manipulation techniques.